Profund Advisors LLC Boosts Stake in Halozyme Therapeutics, Inc. $HALO

Profund Advisors LLC boosted its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 46.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 36,100 shares of the biopharmaceutical company’s stock after buying an additional 11,469 shares during the period. Profund Advisors LLC’s holdings in Halozyme Therapeutics were worth $2,430,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. Clark Capital Management Group Inc. lifted its holdings in Halozyme Therapeutics by 14.4% during the third quarter. Clark Capital Management Group Inc. now owns 202,965 shares of the biopharmaceutical company’s stock worth $14,885,000 after buying an additional 25,582 shares during the period. Intech Investment Management LLC lifted its holdings in Halozyme Therapeutics by 46.0% during the third quarter. Intech Investment Management LLC now owns 148,667 shares of the biopharmaceutical company’s stock worth $10,903,000 after buying an additional 46,850 shares during the period. Allworth Financial LP lifted its holdings in Halozyme Therapeutics by 322.5% during the third quarter. Allworth Financial LP now owns 39,736 shares of the biopharmaceutical company’s stock worth $2,914,000 after buying an additional 30,331 shares during the period. ING Groep NV acquired a new position in shares of Halozyme Therapeutics during the third quarter worth $6,652,000. Finally, Element Squared LLC acquired a new position in shares of Halozyme Therapeutics during the fourth quarter worth $1,193,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on HALO. Benchmark upped their price target on Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, February 19th. Weiss Ratings raised Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research report on Tuesday, May 12th. Wells Fargo & Company upped their price target on Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 19th. Wall Street Zen raised Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday. Finally, TD Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research report on Wednesday, February 18th. Seven equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $80.67.

Halozyme Therapeutics Stock Performance

Shares of HALO stock opened at $68.73 on Wednesday. The business has a fifty day moving average of $65.67 and a 200 day moving average of $68.70. Halozyme Therapeutics, Inc. has a 1 year low of $51.06 and a 1 year high of $82.22. The company has a debt-to-equity ratio of 8.81, a current ratio of 2.76 and a quick ratio of 2.33. The firm has a market capitalization of $8.15 billion, a price-to-earnings ratio of 24.72, a price-to-earnings-growth ratio of 0.28 and a beta of 0.89.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, topping analysts’ consensus estimates of $1.54 by $0.06. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The company had revenue of $376.71 million during the quarter, compared to analysts’ expectations of $358.60 million. During the same quarter in the previous year, the firm posted $1.11 EPS. The firm’s revenue was up 42.2% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. As a group, research analysts expect that Halozyme Therapeutics, Inc. will post 7.66 earnings per share for the current year.

Insiders Place Their Bets

In other Halozyme Therapeutics news, COO Cortney Caudill sold 8,857 shares of the stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $67.64, for a total transaction of $599,087.48. Following the sale, the chief operating officer directly owned 7,055 shares of the company’s stock, valued at approximately $477,200.20. This trade represents a 55.66% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Bernadette Connaughton sold 1,625 shares of the stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $63.48, for a total value of $103,155.00. Following the sale, the director directly owned 38,498 shares in the company, valued at $2,443,853.04. This represents a 4.05% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 120,482 shares of company stock valued at $8,200,842. Company insiders own 2.50% of the company’s stock.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.